

14 June 2024

## CHANGE OF REGISTERED OFFICE

Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX:BOT) (“the Company”), announces the change of its registered office and principal place of business to the following effective immediately:

Suite 3  
41 - 47 Colin Street  
West Perth Western Australia 6005  
Australia

The Company’s telephone number has changed to +61 8 6285 0083.

This ASX announcement is authorised for release by the Board.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis through FDA approval. Botanix is targeting approval for *Sofdra* on June 21, 2024. *Sofdra* is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

#### General enquiries

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

#### Investor enquiries

Hannah Howlett  
WE Communications  
P: +61 450 648 064  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

#### Media enquiries

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)